Business Wire

MA-REINVEST-ROBOTICS

8.12.2021 13:02:06 CET | Business Wire | Press release

Share
Proposed “European AI Act” and “Machinery Product Regulation” Will Hamper Innovation, Stifle Small Businesses and Disrupt Manufacturing, Global Robotics Leaders Warn

The European Commission’s proposed AI Act and updated regulations on machinery products will cause severe damage to European small businesses, robotics companies and innovation, according to four of the most influential voices in robotics and automation. Together, the International Federation of Robotics , the VDMA Robotics + Automation Association , EUnited Robotics and REInvest Robotics urgently call on European policymakers to revisit and amend the proposals.

While all four organizations embrace the European Commission’s vision to maintain safety, protect human rights and create a harmonized framework for artificial intelligence and robotics, the collective sees the following primary issues with the proposed regulations as currently drafted:

  • The mandatory third-party certification requirements will slow tech innovation across Europe.
  • The restrictions will hinder artificial intelligence adoption and put European companies, especially SMEs and startups, at a competitive disadvantage globally.
  • Disruption risk to regional supply chain, manufacturing and logistics operations will rise if the proposals are implemented and adopted.
  • Compliance with regulation worldwide will become more complex and burdensome.

Dr. Susanne Bieller, General Secretary of the International Federation of Robotics, states, “The International Federation of Robotics calls on European policymakers to amend both drafts to balance the protection of citizens with the market’s need to adopt new technologies and ensure a level-playing field for companies. This is not purely a European issue, as the proposed regulations will severely impact all companies bringing robots to the European market. In the long run, the new regulations will be to the disadvantage of European companies, especially SMEs and startups.”

Patrick Schwarzkopf, Managing Director of the VDMA Robotics + Automation Association and Director of EUnited Robotics, comments: “The EU-Commission’s proposals include burdensome regulations of so-called ‘High-Risk AI’ and ‘High-Risk-machinery.’ They include the introduction of extensive mandatory third-party certification requirements, which will discourage the use of AI and slow down innovation across Europe.”

Dr. Esben Hallundbæk Østergaard, the CEO of REInvest Robotics and founder of Universal Robots, comments: “The proposed legislation will hold back European robotics innovation. This is particularly concerning given robotics is the one emerging tech segment where Europe still has an edge globally. Locally, the legislation will negatively affect thousands of small businesses, factories, and manufacturers that rely on robotics and AI to automate critical operations and overcome labor shortages.”

Recommended policy amendments include limiting the scope of the AI Act to essential human rights risks, relying on manufacturers’ self-declaration of conformity in both the AI-Act and Regulation on Machinery Products, increasing enforcement and governance of the existing approach of the machinery directive, and working to create a global framework that increases safety and ethics while maintaining a level playing field. The recent draft report published on the Regulation on Machinery products by the European Parliament’s Committee on Internal Market and Consumer Protection (IMCO) points in this direction by proposing to uphold the crucial principle of self-declaration.

“The approach of the current machinery directive is sufficient. The problem is with governance. We recommend focusing on ensuring that products on the market actually comply with the current EU law, not creating new regulations,” said Østergaard.

For more info, visit reinvestrobotics.com and watch Patrick Schwarzkopf and Dr. Esben Hallundbæk Østergaard discuss the proposals: https://youtu.be/cd0VQx6w-wQ

About REInvest Robotics

REInvest Robotics is a specialized accelerator that invests in startups that democratize the use of robotics to solve real world problems. Founded by robotics pioneer and inventor Esben Hallundbæk Østergaard and Richa Hallundbæk Misri, REInvest Robotics’ vision is to fuel the robotics ecosystem with sustainable investments and help entrepreneurs uplift humankind through robotics. The firm – which provides seed funding and advisory services – specializes in robotics, AI, manufacturing, safety standards and legislation. Successful investments include market leaders Universal Robots and Mobile Industrial Robots (MiR). Learn more at https://www.reinvestrobotics.com/ and follow REInvest Robotics on LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release

The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye